Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741619 | 0.76 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BHRH3TAAR1 | |
| SCHEMBL2741594 | 0.75 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL2741614 | 0.75 | ADRA1A (0.68) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL2741609 | 0.75 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL2741593 | 0.73 | ADRA1A (0.61) | ADRA1AADRA1DADRA1BHRH3TAAR1 | |
| SCHEMBL2741613 | 0.72 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL2741608 | 0.72 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL2741605 | 0.72 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL2741606 | 0.72 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BHRH3HRH4 | |
| SCHEMBL1846168 | 0.71 | TAAR1 (0.55) | ADRA1AADRA1DADRA1BMRGPRX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | ADRA1A 59/4885ADRA1D 55/4885ADRA1B 87/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | ADRA1A 59/4885ADRA1D 55/4885ADRA1B 87/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | ADRA1A 59/4885ADRA1D 55/4885ADRA1B 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.